Depression screening

1. What is it? Any common name for this procedure?

Depression screening is a preventative healthcare process used to identify individuals who may be experiencing clinical depression, even if they haven't yet recognized or reported symptoms. It is usually a brief, self-administered questionnaire or a set of verbal questions asked by a healthcare provider.

The primary goal is not to provide a definitive diagnosis, but to "flag" individuals who require a more in-depth diagnostic evaluation.

Common Names:

• Mental Health Check-up
• PHQ-9 or PHQ-2: Refers to the specific "Patient Health Questionnaire" tools most commonly used.
• Well-Visit Screening: Often integrated into annual physicals or "well-woman/man" exams.
• Perinatal Mood Screening: Specifically for pregnant or postpartum individuals.

2. Common Symptoms / Indications for This Procedure

While current 2026 guidelines from major bodies like the U.S. Preventive Services Task Force (USPSTF) recommend screening for all adults regardless of symptoms, specific "red flags" often prompt more immediate screening:

• Anhedonia: Losing interest or pleasure in activities you normally enjoy.
• Persistent Low Mood: Feeling "down," depressed, or hopeless for most of the day.
• Sleep Disturbances: Difficulty falling/staying asleep, or sleeping too much.
• Energy Loss: Feeling tired or having little energy nearly every day.
• Changes in Appetite: Significant weight loss/gain or poor appetite/overeating.
• Cognitive Issues: Difficulty concentrating, making decisions, or "foggy" thinking.
• Somatic Complaints: Unexplained physical aches, pains, or digestive issues that don't respond to treatment.
• Suicidal Ideation: Thoughts that you would be better off dead or of hurting yourself.

3. List of Associated Diseases and Conditions

Depression is often comorbid with or serves as a risk factor for several chronic conditions:

• Cardiovascular Disease: Depression can worsen heart health and increase the risk of heart attacks.
• Diabetes: There is a bi-directional link between depression and poor glycemic control.
• Anxiety Disorders: These often overlap; providers frequently screen for both simultaneously using tools like the GAD-7.
• Chronic Pain Syndromes: Including fibromyalgia or chronic back pain.
• Bipolar Disorder: Though individuals with a known bipolar diagnosis are often excluded from general depression screening measures to avoid misdiagnosis.
• Substance Use Disorders: Alcohol or drug dependency often co-occurs with clinical depression.

4. List of Screening Tests and Assessment Tools

Standardized, validated tools are used to ensure objective results:

• PHQ-9 (Patient Health Questionnaire-9): The "Gold Standard" 9-item tool that aligns with DSM-5 criteria.
• PHQ-2: A shorter, 2-item "ultra-brief" version used for rapid initial screening.
• BDI-PC (Beck Depression Inventory-Primary Care): Frequently used for adolescents and adults in clinical settings.
• Geriatric Depression Scale (GDS): Specifically designed for older adults (65+).
• EPDS (Edinburgh Postnatal Depression Scale): Used specifically to screen pregnant and postpartum persons.
• Mood and Feelings Questionnaire (MFQ): Often used for adolescents aged 12–17.

5. Am I Eligible for This Procedure?

As of 2026, eligibility is inclusive across the lifespan:

1. All Adults (18+): The USPSTF recommends universal screening, including for those 65 and older.
2. Adolescents (12–17): Screening is recommended as part of routine pediatric care.
3. Perinatal Persons: Pregnant and postpartum individuals are prioritized for screening during and after pregnancy.
4. High-Risk Groups: Individuals with a family history of depression, prior episodes, or significant life stressors.

6. Pre and Post Care

Pre-Care (The Preparation):

• Honesty is Key: There is no physical preparation required. The most important "pre-care" is a commitment to answering questions honestly, even if you feel stigmatized.
• Medication List: Bring a list of any current medications or supplements, as some can mimic or cause depressive symptoms.

Post-Care (The Follow-Up):

• Evaluation: If you screen "positive," the next step is a formal diagnostic interview with a clinician.
• Follow-up Plan: Providers are required to document a follow-up plan for positive screens within 2 days of the encounter.
• Treatment Options: This may include a referral to a therapist (CBT/DBT), starting a pharmacological intervention (SSRIs/SNRIs), or community support groups.
• Suicide Risk Assessment: For those indicating thoughts of self-harm, a more urgent safety assessment is conducted.

7. Days Required for Hospitalization

• Screening Time: 3 to 10 minutes during a standard office visit.
• Hospitalization: 0 Days (Outpatient procedure).

Note: Hospitalization only becomes necessary if the screening leads to a diagnosis that requires intensive inpatient psychiatric care for safety or stabilization.

8. Benefits of Depression Screening

• Early Detection: Identifies depression before it severely impacts work, relationships, or physical health.
• Reduces Suicide Risk: Early intervention is a key component in reducing national suicide rates.
• Improved Chronic Disease Management: Treating depression improves outcomes for related conditions like heart disease and diabetes.
• Reduces Stigma: Normalizing screening as a "vital sign" makes it easier for people to seek help without shame.
• Equitable Care: Routine screening helps ensure that all patients receive care regardless of race, sex, or background.